Paper Details

  1. Home
  2. Paper Details

A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy.

Author: ChoJin Seon, ChoiSee Min, ChoiWoo Suk, ChoiYoung Deuk, ChungByung Ha, HongSung-Hoo, JeonSeong Soo, JeongSeung-Hwan, KangTaek Won, KimByung Hoon, KimSu Youn, KwakCheol, KwonDongdeuk, KwonTae Gyun, LeeHyo Jin, LeeNa-Ri, ParkSung Woo, ShinSang Joon, YeonSang Eun, YunSeok Joong

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluates the effectiveness and safety of abiraterone acetate plus prednisolone (AAP) in both pre- and post-chemotherapy settings for metastatic castration-resistant prostate cancer (mCRPC). The study utilizes real-world data to assess the optimal treatment sequence for AAP in this patient population.
Paper Details　
Original Abstract of the Article :
The proper treatment sequence for administering abiraterone acetate plus prednisolone (AAP) and chemotherapeutic agents has not yet been elucidated for metastatic castration-resistant prostate cancer (mCRPC). Hence, this study evaluated the effectiveness and safety of AAP in pre- and post-chemothera...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482671/

データ提供：米国国立医学図書館（NLM）

Finding the Right Path for Metastatic Castration-Resistant Prostate Cancer

Metastatic castration-resistant prostate cancer (mCRPC), a complex and aggressive form of cancer, can be as challenging to treat as navigating a sandstorm. This research explores the effectiveness and safety of abiraterone acetate plus prednisolone (AAP) in treating mCRPC, comparing its use in pre- and post-chemotherapy settings. The study, like a skilled camel navigator, analyzes the clinical outcomes and safety profiles of AAP in these two different treatment sequences. The findings suggest that AAP, while offering benefits, requires careful consideration of the optimal timing for its administration in the complex landscape of mCRPC treatment.

A Promising New Tool for Managing Metastatic Castration-Resistant Prostate Cancer

This research provides valuable insights into the use of AAP in treating mCRPC. The study's findings suggest that AAP, while offering benefits, requires careful consideration of the optimal timing for its administration to achieve the best clinical outcomes for individual patients.

Navigating the Desert of Prostate Cancer Treatment

This research sheds light on the complex landscape of mCRPC treatment, emphasizing the need for individualized approaches. The findings highlight the importance of carefully considering the timing and sequence of treatment options, such as AAP, to maximize therapeutic effectiveness and minimize potential side effects. This discovery is like finding a hidden spring in the desert of prostate cancer treatment, offering a potential source of relief for those struggling with this challenging condition.

Dr.Camel's Conclusion

This research highlights the evolving landscape of mCRPC treatment, emphasizing the importance of personalized approaches. The study's findings offer valuable insights into the use of AAP and its potential benefits. This discovery is like finding a new oasis in the desert of prostate cancer treatment, offering a potential source of relief for those struggling with this complex condition.

Date :
  1. Date Completed 2023-09-06
  2. Date Revised 2023-09-09
Further Info :

Pubmed ID

37668202

DOI: Digital Object Identifier

PMC10482671

Related Literature

Article Analysis
・Side Effects of abiraterone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.